近年来,缺血性疾病的的发生率日益增多,多种新型的组织损伤标志物逐渐应用于临床,用来早期诊断急性缺血性疾病,其中缺血修饰白蛋白(ischemia modified albumin,IMA)已经引起临床的广泛关注,并相继对其展开多项研究,旨在降低心脑血管病高危个体的漏诊率及给早期干预提供依据 In recent years, the incidence of ischemic diseases is increasing, a variety of new tissue damage markers gradually applied to clinical, used to early diagnosis of acute ischemic disease, including ischemia modified albumin (ischemia modified albumin, IMA) Has aroused widespread clinical attention, and have carried out a number of its studies in order to reduce the risk of misdiagnosis of individuals with cardiovascular and cerebrovascular disease and to provide a basis for early intervention